Getting Mounjaro: the decision, the process, and what to expect

Do you meet the criteria, and does that mean the NHS will prescribe it?

The licence for Mounjaro covers adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. That is the private prescription threshold, but the NHS applies a considerably tighter filter. Tirzepatide became available on the NHS through a phased rollout that started in June 2025. At the time of writing, the first cohort requires a BMI of 40 or above plus four of five specific conditions. A second cohort covering BMI 35–39.9 with four of those conditions was activated in June 2026. Further phases are planned through 2027. So a person with a BMI of 33 and high blood pressure may be fully within the licensed criteria and yet nowhere near NHS eligibility right now.

That gap between who the medicine is licensed for and who the NHS currently funds it for is the central practical question when you start thinking about getting Mounjaro. Our full Mounjaro guide covers the licensing picture in detail. Concerns about future access are also worth understanding before committing to a route. The short answer is: check both thresholds, not just one.

NHS route or private route: the honest trade-offs

If you do meet NHS criteria, the GP route is free and comes with wraparound lifestyle support, but your practice has to be participating in the 2026/27 contract, and the medicine's availability still varies by area. Specialist NHS weight management services also prescribe it, though waiting lists are long in most regions. Neither route comes with any guarantee of speed.

The private route, via a GPhC-registered online pharmacy, requires no referral and no waiting list. A prescriber still reviews your case (thoroughly) but the process moves faster. You can read about what private treatment costs across the market to set realistic expectations; prices have risen since Eli Lilly adjusted UK list pricing in late 2025. The right question is not simply which route is cheaper, but which route will actually get you started with proper clinical oversight. Our clinical team reviews every consultation personally, the same day it is submitted.

One practical thing: a named prescriber, not software, reads your answers. That distinction matters more than it might sound, it is how clinical edge cases get caught and managed safely, rather than auto-approved.

What the process of getting Mounjaro actually involves

Via a regulated private pharmacy, the sequence is straightforward. You complete a health questionnaire covering your weight, medical history, any medicines you take, and your goals. A GPhC-registered Independent Prescriber reviews the whole submission. If treatment is clinically appropriate, a prescription is issued and your pens are dispensed from a pharmacy operating within the licensed UK supply chain.

Identity and current weight are verified, at nume that means photo ID and live weight confirmation on video, every time, not just at sign-up. This is not box-ticking: it is how a responsible pharmacy checks that dose decisions are grounded in real, current data. If you order before noon on a weekday and your prescription is approved, your treatment is dispatched the same day and delivered the next working day by DPD. The box arrives plain and unbranded; you get a tracking notification on your phone. Inside is the KwikPen, ready to refrigerate. First-time patients often tell us the whole thing felt less clinical and more straightforward than they expected.

For a broader sense of how supported treatment compares to going it alone, the weight loss treatment overview is a good place to look alongside this page. And if you have read accounts of people struggling after stopping, what happens to weight after you stop is worth understanding before you start.

Side effects and ongoing considerations when getting tirzepatide

Starting Mounjaro (or stepping up through the dose schedule) typically brings some gastrointestinal adjustment. Nausea is the most commonly reported effect; loose stools, constipation, indigestion and fatigue also appear in the trial data and in clinical practice. These effects tend to be most noticeable in the first week or two at a new dose and settle for most people. The NHS patient information for tirzepatide, available at nhs.uk/medicines/tirzepatide, lists the full side-effect profile clearly and is worth reading before you begin.

A few things deserve particular attention. Women using oral contraceptive pills should discuss the interaction with their prescriber: absorption of the pill may be reduced during the first four weeks of tirzepatide treatment and after each dose increase, so additional contraception is advised during those windows. Surgery is another point, anyone taking Mounjaro should tell their anaesthetist before any planned procedure. If you notice severe, persistent stomach pain, particularly pain that seems to reach through to your back, get medical help promptly; this can be a sign of pancreatitis, and the MHRA has highlighted it as a known risk requiring urgent attention.

Some people notice unexpected changes while on treatment. Hormonal side effects and unexpected weight changes during treatment are questions our prescribers field regularly. Answers to those are available in detail. The general FAQs cover a wider range of practical questions if you want to keep reading.

Getting Mounjaro the right way means clinical review upfront and proper support throughout. If you want to check whether you're likely to be eligible, checking your eligibility with our prescribers costs nothing and takes a few minutes.